Abstract
Some patients with lung cancer have abnormalities in the anaplastic lymphoma kinase (ALK) protein. Investigators conducted a phase I trial of an orally delivered small-molecule inhibitor — crizotinib (PF-02341066) — that preferentially inhibits the ALK and c-met (hepatocyte growth factor) receptor tyrosine kinases in solid tumors. The drug's manufacturer partially funded the study. In the dose-escalation phase of the trial (increasing from 50 mg once daily to 300 mg twice daily), two patients with non–small-cell lung cancer (NSCLC) and an ALK rearrangement exhibited response to the drug. That prompted screening of an expanded cohort of about 1500 NSCLC patients for ALK …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
